Clinical trials

Various pharmaceutical companies conduct clinical trials for the development of new effective treatments for various skin conditions. Dr Kim completed his Master of Medicine from the University of Sydney through a clinical trial on vitamin D, and has been involved in a number of other clinical trials.

Cornerstone Dermatology has special interest in clinical trials. Please enquire about ongoing clinical trials the clinic is currently involved in.


Currently recruiting Clinical Trials

Atopic Dermatitis (Eczema)

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis – Click here

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis – Click here

Alopecia Areata

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata – Click here

 

For expressions of interest to participant in a clinical trial, please contact our Clinical Trials Team on: 

Phone: (07) 3397 3200

Fax:      (07) 3397 3900

Email:  trials@cornerstonederm.com.au

Principal Investigator:

  • Dr Young Jin Kim

Sub Investigator:

  • Dr Shiva Baghaei

Clinical Nurse Specialist/Nurse Researcher:

  • Teagan Holland
  • Margaret Anders

Successful Trial Medications

Our Clinical Trial team has worked with the following medications which are now approved for use in Australia for the following conditions:

 

Atopic Dermatitis (Eczema)

  • Dupilumab (Dupixent)
  • Upadacitinib (Rinvoq)

 

Hidradenitis Suppurativa (HS)

  • Adalimumab (Humira)

Psoriasis

  • Ixekizumab (Taltz)
  • Apremilast (Otezla)
  • Adalimumab (Humira)
  • Secukinumab (Cosentyx)
  • Guselkumab (Tremfya)
  • Tildrakizumab (Ilumya)
  • Risankizumab (Skyrizi)
  • Deucravacitinib (Sotyktu)

Chronic Spontaneous Urticaria (CSU)

  • Omalizumab (Xolair)